Reviewing AbCellera Biologics (NASDAQ:ABCL) and Cytokinetics (NASDAQ:CYTK)

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares AbCellera Biologics and Cytokinetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AbCellera Biologics -218.54% -15.35% -10.84%
Cytokinetics -686.63% N/A -48.26%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for AbCellera Biologics and Cytokinetics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AbCellera Biologics 1 1 8 2 2.92
Cytokinetics 1 1 19 0 2.86

AbCellera Biologics currently has a consensus target price of $16.55, indicating a potential upside of 48.79%. Cytokinetics has a consensus target price of $106.67, indicating a potential upside of 100.61%. Given Cytokinetics’ higher probable upside, analysts clearly believe Cytokinetics is more favorable than AbCellera Biologics.

Risk & Volatility

AbCellera Biologics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.

Institutional and Insider Ownership

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares AbCellera Biologics and Cytokinetics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AbCellera Biologics $67.85 million 53.53 -$146.41 million ($0.48) -23.17
Cytokinetics $113.29 million 65.38 -$784.96 million ($6.04) -8.80

AbCellera Biologics has higher earnings, but lower revenue than Cytokinetics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Summary

AbCellera Biologics beats Cytokinetics on 9 of the 15 factors compared between the two stocks.

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

About Cytokinetics

(Get Free Report)

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.